Naftilux

Quick links to important sections

Naftilux

Method of action: Peripheral Vasodilators

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Naftilux

What is Naftilux? Overview and Classification

Property Description
Active ingredient Naftidrofuryl oxalate
Form Oral capsule/tablet, Parenteral solution
Pharmacological class Peripheral Vasodilator, Vasoactive Agent
General purpose Optimizing tissue metabolism and circulation
Origin Synthetic small molecule

What is Naftilux and its Pharmacological Classification?

Naftilux is a specific trade name for a medicine containing the active ingredient Naftidrofuryl oxalate, which is a synthetic medicinal entity. It is formally recognized as a peripheral vasodilator and a vasoactive agent, confirming its role in acting directly on blood vessels and modifying circulatory function. The active substance falls under the C04AX21 segment of the Anatomical Therapeutic Chemical (ATC) system. The compound is clinically recognized for its general use in supporting circulation in conditions affecting the limbs, distinguishing it from agents focused solely on cardiovascular or central circulation.

The compound serves as a vasoactive agent intended to support and manage symptoms related to reduced blood flow in the periphery. The medicine helps optimize cellular function by influencing the mechanisms that control local circulation and energy use.

Naftidrofuryl's Composition and Available Forms

The medicine is formulated as a single-ingredient product, containing only Naftidrofuryl oxalate. While the Naftilux brand is typically associated with the oral capsule form, the Naftidrofuryl INN itself is provided for oral administration as tablets or capsules, and also exists as a parenteral solution for use in contexts requiring direct injection or intravenous infusion. Its synthetic, non-biological origin ensures a chemically precise and consistent composition across all dosage forms.

General Purpose: Optimizing Circulation and Cellular Metabolism

The general benefit of Naftidrofuryl stems from its dual action, which not only promotes physical vasodilation but also enhances the metabolic function of oxygen-deprived tissues. This vasoactive action is achieved through several mechanisms, including the selective blockade of certain serotonin 5-HT2 receptors. This medicine is designed to help maintain the essential balance between blood supply and tissue energy demands by acting on specific blood vessel receptors.

By promoting the more efficient utilization of oxygen and glucose by tissues, Naftidrofuryl addresses the critical physiological deficit present when blood supply is limited. This protective and metabolic supporting action helps maintain the overall integrity and function of tissues, which constitutes the medicine's overarching therapeutic goal.

Regulatory References

  1. serotonin 5-HT2 receptors
  2. EMA Assessment Report

What side effects are possible with Naftilux?

Possible Side Effects and Safety Information

The safety profile for Naftilux (naftidrofuryl) is characterized by common, generally non-severe reactions primarily affecting the gastrointestinal and nervous systems, alongside a recognized risk of serious, albeit rare, systemic complications.

Adverse Reaction Category Examples / Frequency Classification
Common / Frequently Reported Gastrointestinal discomfort (nausea, vomiting, abdominal pain), Nervous system disorders (dizziness, vertigo, headache)
Rare / Uncommon Allergic reactions (rash, itching), Liver function abnormalities, Renal calcic oxalate lithiasis (kidney stones)
Serious Adverse Reactions Acute cytolytic hepatitis (severe liver damage), Anaphylactic-type reactions, Acute renal failure (primarily with high intravenous doses in patients with renal impairment)

Key Safety Considerations

  • Serious Liver Damage: Cases of acute cytolytic hepatitis have been reported, representing a serious but uncommon risk that necessitates careful monitoring of liver function during treatment.
  • Renal Risk: While uncommon with standard oral dosing, high-dose intravenous administration has a documented potential to cause acute renal failure due to the precipitation of calcium oxalate crystals. Caution is therefore required, particularly in individuals with pre-existing kidney problems.
  • Contraindications and Restrictions: Naftilux is generally not recommended for use in individuals with known hypersensitivity to the drug or in those with severe cardiac conduction abnormalities. Caution is advised in patients with a history of peptic ulcers or pre-existing esophageal disease, due to potential exacerbation and rare reports of esophageal ulceration.
  • Drug Interactions: Regulatory documents note the potential for interaction with anticoagulant and antiplatelet medications, which may increase the risk of bleeding. Close surveillance is recommended when these medications are used concurrently.

This information is based strictly on governmental regulatory documents and clinical trial summaries, detailing the officially documented risks and limitations associated with the drug.

Overdose and Emergency Response

Overdose and when to seek help

This section describes the officially documented manifestations and required emergency procedures for an overdose of Naftidrofuryl oxalate, based strictly on government regulatory documents.


Documented Overdose Manifestations

Official regulatory labeling identifies specific severe clinical manifestations associated with Naftidrofuryl oxalate overdose:

  • Depression of cardiac conduction (a cardiovascular effect)
  • Convulsions (a neurological effect)

These effects define severe cases that necessitate immediate, specialized medical intervention and continuous observation.


Emergency Actions and Monitoring Requirements

Urgent medical care is required immediately upon suspected overdose or the onset of these symptoms. Management is symptomatic and supportive, as no specific antidote is known.

Action/Requirement Regulatory Statement Summary
Stomach Procedures The stomach must be emptied via gastric lavage and emesis; activated charcoal may be used.
Monitoring Continuous monitoring of cardiovascular function and respiration is mandated.
Supportive Treatment Diazepam is specified for managing convulsions, and electrical pacemaking or isoprenaline should be considered for severe cardiorespiratory issues.

Immediate professional medical attention is essential for all instances of suspected overdose to initiate monitoring and supportive procedures outlined in the official regulatory documentation.

Therapeutic Uses of Naftilux

This medication is commonly used to provide symptomatic support for Peripheral Vascular Disorders and Cerebrovascular Insufficiency. The primary conditions it helps manage include Peripheral Occlusive Arterial Disease (POAD), intermittent claudication, chronic cerebral ischemia, and related symptoms like trophic ulcers or severe rest pain. This therapeutic support is focused on addressing the cramping and pain in the legs that typically begins during walking. It may assist with increasing the distance a patient can travel without discomfort. Beyond mobility, it is considered relevant in clinical settings marked by conditions where functional stability becomes affected due to chronic circulation issues, helping to ease the overall symptomatic burden of these long-standing deficits.

“The medication assists in supporting functional stability by helping to ease symptoms that interfere with routine activities.”

Quick Fact: Relief for Exertion-Induced Leg Cramping
Main Use Context: Symptomatic management of symptoms that interfere with daily functioning due to chronic vascular issues during physical activity.
Primary Benefit: Supports patients during difficult episodes by easing distress and improving day-to-day comfort during symptomatic periods.

Regulatory References

  1. National Institute for Health and Care Excellence (NICE)

Eligibility and Restrictions for Use

Who Can and Cannot Use Naftilux?

The eligibility for Naftilux (Naftidrofuryl oxalate) is strictly defined by regulatory health authorities and is primarily established for the adult population. The medicine is mainly used in older adults.

Absolute Contraindications

Naftilux is contraindicated and must not be used in patients with:

  • Known hypersensitivity to the active substance or excipients.
  • A history of hyperoxaluria or recurrent calcium-containing kidney stones.
  • Certain pre-existing cardiac function disorders, specifically Atrioventricular (AV) block.

Restricted Populations and Age Limitations

Population Group Regulatory Status
Paediatric Population Not indicated; safety and efficacy have not been established.
Pregnancy Use is not advisable due to a lack of relevant clinical data.
Lactation Should not be used in the absence of specific data on excretion in human milk.
Organ Impairment Caution is required for use in patients with renal insufficiency, hepatic insufficiency, or severe cardiac insufficiency.

Use is restricted in children and during pregnancy/lactation due to insufficient regulatory data, while conditions affecting oxalate metabolism or cardiac conduction prohibit its use entirely.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents indicate that Naftilux (Naftidrofuryl oxalate) does not have formally listed drug-drug interactions, or documented metabolic or pharmacodynamic interactions with other medicines.

Administration and Substance-Related Restrictions

The primary constraints documented in prescribing information are linked to the drug's composition (oxalate) and its administration route, creating specific substance and timing requirements.

1. Administration-Timing Rules

Interaction-Related Restriction Official Regulatory Constraint
Liquid Requirement The capsule must always be taken with a sufficient amount of water to prevent the local adverse event of oesophagitis.
Meal Timing Co-administration is recommended during meals with liquid.
Bedtime Restriction Administration without liquid before going to bed is officially noted as a risk factor for local oesophagitis.

2. Substance Interaction Contraindication

Interacting Component Official Contraindication
Oxalate The medicine is contraindicated in patients with a history of hyperoxaluria or recurrent calcium-containing kidney stones, due to the active ingredient's potential to modify urine composition and promote stone formation.

Mechanism of Action

Naftilux (naftidrofuryl oxalate) functions through a dual pharmacodynamic mechanism involving vascular and cellular metabolic pathways. In the vasculature, the compound acts as a selective antagonist at 5-HT2 serotonin receptors, primarily localized on vascular smooth muscle cells and platelets. This interaction blocks the vasoconstrictive signaling cascade initiated by endogenous serotonin binding. The resultant inhibition of receptor-mediated vascular smooth muscle contraction leads to arteriolar vasodilation, specifically in peripheral and cerebral arterial beds, which modulates systemic blood flow distribution.

Intracellularly, naftidrofuryl modulates cellular energy metabolism, particularly under conditions of low oxygen availability. The drug facilitates the aerobic utilization of glucose and oxygen by improving the efficiency of the mitochondrial respiratory chain. This metabolic modification is associated with an enhancement of ATP synthesis and a reduction in the lactate-to-pyruvate ratio within affected cells. Downstream, this cellular energy optimization and the systemic vasodilation result in a coordinated system-level modulation of tissue perfusion and cellular bioenergetics in ischemia-prone tissues.

Dosage and Administration Information

How to Use Naftilux: Administration Guidelines

Naftidrofuryl oxalate is primarily used via the oral route for long-term treatment, though a parenteral solution is available for intravenous administration in supervised settings.


Standard Oral Dosing Protocol

The medicine is typically prescribed in an oral capsule or tablet form at a single dose of 100 mg or 200 mg. The standard regimen requires the medicine to be taken three times daily (t.i.d.). This frequency results in a total daily dose that generally ranges from 300 mg to 600 mg, with 600 mg being the maximum recommended daily amount.


Administration Requirements and Duration

For proper use, the oral dose must be swallowed whole—it must not be chewed, crushed, or opened—and taken during a meal. Instructions for use include taking the dose with a sufficient amount of water (such as a full glass) to ensure the capsule passes completely and to prevent local irritation. Patients are specifically instructed to avoid taking the medicine immediately before lying down without fluid.

Treatment with Naftidrofuryl oxalate typically involves a minimum course duration of three months. The decision to continue beyond this initial period is based on the patient's response and is determined by the supervising physician. The use of this medicine is not indicated in the pediatric population, as the safety and efficacy have not been established in children.

Administration Constraint Rule
Frequency Three times daily (t.i.d.)
Intake Method Swallow capsule/tablet whole
Minimum Duration Three months

Recent Clinical Evidence

Research Evidence / Overview of Studies for Naftilux


Evidence for Symptomatic Relief of Intermittent Claudication

Research exploring Naftidrofuryl oxalate has primarily focused on intermittent claudication, a condition research was designed to explore, which is the cramping or pain in the legs that occurs during walking due to reduced blood flow. The primary evidence base explored for this condition comes from short-term, randomized controlled trials (RCTs). These studies randomly assigned adult patients to receive either the medicine or a placebo (an inactive substance) over a period of several months. The trials enrolled adult patients whose symptoms continued despite initial conservative management.

In these trials, researchers primarily monitored functional measures to see how the condition evolved in the observed populations. Outcomes related to physical discomfort that research examined included standard measurements of Pain-Free Walking Distance and Maximal Walking Distance on a treadmill. Larger analyses of the combined data suggest patterns related to measured changes in walking distance compared to placebo conditions. However, the findings describe group patterns, not personal outcomes, and research does not determine whether an individual will respond similarly.


Research on Other Peripheral Vascular Conditions

Naftidrofuryl oxalate was also studied for a wider range of conditions characterized by fluctuating or episodic manifestations of poor peripheral circulation. This part of the evidence base consists mainly of older, smaller randomized controlled trials and literature reviews. Research explored its application in conditions such as trophic ulcers (skin damage), rest pain, and symptoms linked to chronic cerebral circulation deficits. The data for these broader indications were noted as limited and heterogeneous in reviews by major guideline bodies. The research base for these secondary uses is less consolidated.


Long-Term Studies and Follow-up Durations

The evidence contributes to the broader evidence landscape by highlighting what has been observed so far, but the follow-up durations were limited. The primary RCTs typically monitored patients over an interval of three to six months. This means that the research describes observed patterns related to short-term changes. The trials were not designed to provide comprehensive data on sustained outcomes over years, limiting information on the maintenance of functional gains or major clinical endpoints such as major cardiovascular events, hospitalization rates, or survival.


What Research Gaps and Uncertainties Remain

A significant gap is the limited information for long-term outcomes that would capture the medicine's impact on systemic health and disease progression over several years. Furthermore, comparative evidence is lacking regarding how Naftilux performs against modern non-pharmacological approaches, such as formal supervised exercise programs, which are now standard care.

Key Studies & References

  1. Intermittent claudication: clinical management of peripheral arterial disease.

Frequently Asked Questions (FAQ)

Common questions about Naftilux (FAQ)


Q: What is the main purpose of taking Naftilux?

According to the official product information, the main purpose of this medicine is the symptomatic treatment of disorders that affect the blood vessels in the limbs, known as peripheral vascular disorders. Regulatory documents describe its use for the symptomatic treatment of conditions like intermittent claudication (cramp-like leg pains when walking).


Q: What type of condition is Naftilux generally used to treat?

Regulatory documents state that Naftilux is used to describe treatment for symptoms associated with peripheral vascular diseases. These conditions include cramp-like pain in the legs when walking (intermittent claudication), severe pain in the legs while at rest, and night cramps.


Q: Is Naftilux available over the counter, or do I need a prescription?

Official regulatory status indicates that Naftilux (Naftidrofuryl oxalate) is typically classified as a Prescription Only Medicine (POM) in the markets where it is authorized. This status means the medicine requires a prescription from a healthcare professional.


Q: Is Naftilux appropriate for older adults or seniors?

Regulatory information indicates that the medicine is primarily used in elderly patients. Information in the product label notes that severe kidney or liver impairment may necessitate dose adjustments, which are determined by a healthcare provider.


Q: Are there known safety warnings about using Naftilux during pregnancy?

Official prescribing information advises that the use of the medicine is not advisable during pregnancy. This precautionary statement is issued due to the absence of relevant clinical data to fully establish its safety in this population.


Q: What is the information about Naftilux use while breastfeeding?

According to the official product information, the medicine should not be used by women who are breastfeeding. This precautionary guidance is given because there is no specific data available regarding its excretion into human milk.


Q: Does Naftilux interact with common pain relievers like ibuprofen?

Regulatory documents state that Naftilux generally does not have formally listed drug-drug interactions. However, the prescribing information indicates the medicine may interact with other agents that affect blood flow, such as anticoagulants and antiplatelet drugs.


Q: Are there any specific supplements or vitamins that should be avoided when using Naftilux?

Official patient guidance states that a healthcare provider should be informed about all products being taken. This includes any herbal, complementary, or other non-prescription medicines, to ensure there are no potential interactions.


Q: What are the most common side effects listed for Naftilux?

Official product information reports that some side effects are uncommon, meaning they affect a small number of people. These commonly reported uncommon effects include feeling sick (nausea), diarrhea, vomiting, stomach ache, and skin rash.


Q: Is feeling tired or drowsy a known side effect of Naftilux?

Medical summaries based on regulatory reports list dizziness, headache, and insomnia (difficulty sleeping) as potential side effects. These are central nervous system effects that may be associated with feelings of altered awareness.


Q: Is it normal to have mild stomach upset when first starting Naftilux?

Official product information notes that feeling sick (nausea) and stomach ache are listed as uncommon side effects. The administration guidelines state that the capsules must be taken with meals, and this method of intake may be associated with reduced risk of stomach discomfort.


Q: What should be done if a potential serious side effect occurs?

Regulatory patient information states that a healthcare provider should be informed immediately if certain serious changes are noticed. This includes signs of liver damage (yellowing of the skin/eyes, or jaundice) or if a patient experiences neurological symptoms or disorders of cardiac rhythm.


Q: Does Naftilux have any known restrictions related to driving or operating machinery?

Official information mentions that side effects such as dizziness and blurred vision may occur. As these symptoms can affect reaction time and perception, caution should be exercised before driving or operating machinery.


Q: Is there any research that links Naftilux to liver function issues?

Yes, official regulatory reports confirm that liver damage (such as hepatitis or liver failure) has been reported as an adverse effect. These instances are reported rarely; questions regarding monitoring or follow-up should be directed to a healthcare provider.


Q: Does Naftilux contain any ingredients that might cause an allergic reaction?

The medicine is contraindicated (use is restricted) for individuals with known hypersensitivity or allergic reaction to naftidrofuryl or any of its components, as noted in the official regulatory documents.


Q: Is Naftilux approved by the FDA (or equivalent regulatory body)?

Naftilux (Naftidrofuryl oxalate) holds authorization as a Prescription Only Medicine (POM) in major European countries (EU/UK). Authorization and official labeling are overseen by bodies like the EMA and MHRA.


Q: Can people with kidney problems use Naftilux?

Regulatory documents state that Naftilux is contraindicated for patients with a history of recurrent calcium oxalate kidney stones or hyperoxaluria (too much oxalate in the urine). Caution is also advised in cases of severe kidney impairment.


Q: Is Naftilux safe for people who have heart conditions?

Official product information states that the medicine is contraindicated in patients with certain severe cardiovascular conditions. These include severe heart failure and unstable angina pectoris (a serious type of chest pain).


Q: Are there known food or drink restrictions while taking Naftilux?

Official administration instructions require that the capsules must be swallowed whole with a glass of water during meals. There is a specific warning to avoid taking the capsule without liquid immediately before lying down.


Q: What are the specific conditions that would prevent someone from being eligible for Naftilux?

Regulatory documents list several conditions that restrict eligibility. These contraindications include known hypersensitivity, severe heart failure, unstable angina pectoris, severe liver or kidney impairment, a history of recurrent kidney stones, and use in the pediatric population.


Q: Does Naftilux impact mood or mental focus?

Official medical summaries have reported side effects such as anxiety and insomnia (difficulty sleeping). These central nervous system effects may impact a person's mood or ability to focus.


Q: Is Naftilux sometimes used for purposes other than the main listed one?

Official regulatory documents list the treatment of symptoms like night cramps and severe pain in the legs at rest. It is also indicated for managing symptoms associated with Raynaud's syndrome in addition to its primary use for intermittent claudication.

How should Naftilux be stored and disposed of?

The storage and disposal of Naftilux (Naftidrofuryl oxalate) must adhere strictly to the conditions specified in official regulatory labeling to ensure product stability and environmental safety.

Storage Requirements

Condition Requirement (Official Label)
Temperature Limit Do not store above 25, C. The product must not freeze.
Protection Store in the original package to protect from light and moisture.
Child Safety Keep the medicine out of the sight and reach of children.

Disposal Instructions

Unused or expired Naftilux must be disposed of in accordance with national regulations for pharmaceutical waste. The medicine must not be thrown away with household garbage and should not be allowed to enter the sewage system or ground water.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Naftilux found in:

A-Z Index: